<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Investment potential on FinanClub</title>
    <link>https://finan.club/tags/investment-potential/</link>
    <description>Recent content in Investment potential on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 31 Jan 2024 09:04:21 +0000</lastBuildDate><atom:link href="https://finan.club/tags/investment-potential/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>ARDX</title>
      <link>https://finan.club/us/ardx/</link>
      <pubDate>Wed, 31 Jan 2024 09:04:21 +0000</pubDate>
      
      <guid>https://finan.club/us/ardx/</guid>
      <description>score:71
Chances: The company has achieved significant commercial progress, with one of its medication expected to generate over $1 billion in annual sales revenue at peak. Investors tend to be attracted to stocks that trade at a cheap price, offering the possibility of great returns for not a large amount of capital invested.</description>
    </item>
    
    <item>
      <title>IBRX</title>
      <link>https://finan.club/us/ibrx/</link>
      <pubDate>Thu, 28 Dec 2023 09:05:11 +0000</pubDate>
      
      <guid>https://finan.club/us/ibrx/</guid>
      <description>score:64
Chances: ImmunityBio, Inc. is participating in the 35th Annual Piper Sandler Healthcare Conference, which is a positive sign for potential collaborations and investor interest. The new data showing the potential benefits of Memory Cytokine-Enriched Natural Killer cells (M-ceNK) for patients with small cell lung cancer and other types of neuroendocrine tumors indicates promising developments in the companyâ€™s immunotherapy platform.</description>
    </item>
    
  </channel>
</rss>
